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Summary
 
T cell recruitment to extralymphoid tissues is fundamental to the initiation and perpetuation of
the inflammatory state during immune and autoimmune responses. Interleukin (IL)-15 is a proin-
flammatory cytokine whose described functions largely overlap with those of IL-2. The latter is
 
attributable in large part to its binding of the heterotrimeric receptor that contains the 
 
b
 
 and
 
g
 
 chains of the IL-2R in combination with an unique IL-15R
 
a
 
 chain. However, unlike IL-2,
IL-15 and its receptor have a wide tissue and cell type distribution, including endothelial cells.
Here, we examine the effect of IL-15 on hyaluronan expression by endothelial cells, and investi-
gate its role in vivo in promoting the extravasation of antigen-activated T cells through a CD44-
dependent pathway. The expression of hyaluronan on primary endothelial cells and microvascular
endothelial cell lines is induced by IL-15, whereas IL-2 has no such activity. Moreover, intraperi-
toneal administration of IL-15 or TNF-
 
a
 
 in the absence of other exogenous proinflammatory
stimuli allows the extravasation of superantigen-stimulated T cells into this site in vivo
 
 
 
in a
CD44-dependent manner. T cell recruitment induced by IL-15
 
 
 
requires expression of an intact
IL-2R
 
b
 
 chain, indicating that IL-15 operates in this context through the traditional IL-15R.
 
 
 
The
results suggest that IL-15 can regulate endothelial cell function and thereby enables a CD44-initi-
ated adhesion pathway that facilitates entry of activated T lymphocytes into inflammatory sites.
They further demonstrate a novel role for IL-15 (distinct from any of IL-2) in regulating micro-
vascular endothelial cell adhesive function, help to understand the role of IL-15R expression on
endothelium, and further support a central position for this cytokine in orchestrating multiple
sequential aspects of T cell effector function and therefore chronic inflammatory processes.
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T
 
he specificity and regulation of leukocyte extravasation
results in part from the differential expression of vari-
ous types of adhesion receptors on endothelium within tis-
sues and on leukocyte subsets, and partially from the fact
that these receptors can act in sequential fashion. Our labo-
ratory has been engaged in the description and character-
ization of a novel primary adhesion (rolling) interaction be-
tween the activated form of the cartilage link proteoglycan
family member CD44 on lymphocytes and its major ligand,
the glycosaminoglycan hyaluronan (HA)
 
1
 
 on endothelial
cells (ECs) (1). We have shown in a mouse model that this
interaction can function in an extravasation pathway that
results in the egress of antigen-activated lymphocytes in an
inflamed vascular bed (2, 3). We have further demonstrated
that HA expression is increased on microvascular primary
EC cultures and EC lines in response to proinflammatory
stimuli such as TNF-
 
a
 
, IL-1
 
b
 
, and LPS in vitro. This ele-
vated expression results in increased interactions of activated
lymphocytes with endothelium under shear forces (4). These
observations have lead us to propose that the activated form
of CD44 is induced on lymphocytes as a result of antigen
stimulation, followed by release of activated cells from sec-
ondary lymphoid sites into the peripheral circulation. Acti-
vated CD44 would then function to initiate lymphocyte
extravasation at sites of antigen localization or inflamma-
tion, where HA has been upregulated on the endothelium.
In support of this model, circulating lymphocytes bearing
 
1
 
Abbreviations used in this paper:
 
 bPG, bovine proteoglycan; CFDA-SE,
5-(and-6)-carboxyfluorescein diacetate, succinimidyl ester; EC, endothe-
lial cell; HA, hyaluronan; HUVEC, human umbilical vein endothelial
cell; ICAM, intracellular adhesion molecule; MLN, mesenteric lymph
node; RT-PCR, reverse transcription polymerase chain reaction; SA-PE,
phycoerythrin-labeled Streptavidin; SEB, Staphylococcal enterotoxin B;
VCAM, vascular cell adhesion molecule. 
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IL-15 Regulates T Cell Trafficking through CD44
 
activated CD44 have been shown to be elevated during auto-
immune exacerbations in both arthritis and systemic lupus
erythematosus in humans (5). This finding suggests that such
cells represent a pathogenically important subset of acti-
vated T cells and may serve as a reliable marker for autoim-
mune or other chronic inflammatory disease activity.
IL-15 is a cytokine originally identified as a T cell growth
factor and described to have biological activities similar to
IL-2 (6, 7). These properties include induction of T cell
proliferation; potent T cell chemotaxis; costimulation of B
cell growth and isotype switching; and promotion of natu-
ral killer cell growth, cytotoxicity, and cytokine production
(8). IL-15 has also been reported to inhibit apoptosis and to
enhance the survival of activated T cells in vivo (9, 10).
However, unlike IL-2, IL-15 is expressed in diverse types
of tissues, including skeletal muscle and kidney, as well as
in a variety of cell types such as activated monocytes, fibro-
blasts, and keratinocytes. IL-15 generally mediates its activ-
ity through a heterotrimeric receptor consisting of a unique
IL-15R
 
a
 
 chain in combination with the IL-2R
 
b
 
 and 
 
g
 
chains (8). Like IL-15, the unique IL-15R
 
a
 
 chain has a broad
tissue distribution, suggesting potential functions for this
cytokine outside of the hematolymphoid system. IL-15 thus
has been shown recently to have anabolic effects on skeletal
muscle (11) and may serve as an angiogenic factor (12).
IL-15 has been suggested to play a role in the setting of
the chronic autoimmune disease rheumatoid arthritis, par-
ticularly in the recruitment and activation of synovial T cells.
This cytokine has been reported to be elevated within the
synovial fluid of affected patients, and administration of IL-15
into the hind footpad of mice resulted in an enhanced
mononuclear cell infiltrate, predominantly T cells, at the site
of injection, although the mechanism for this was not elu-
cidated (8, 13). Recently, in a mouse model of collagen-
induced arthritis, a soluble form of the IL-15R
 
a
 
 chain was
shown to be effective in ameliorating disease (14). This cyto-
kine also has been shown to have clear effects on chemo-
attraction and migration of lymphocytes (8, 15). However,
a pivotal element of inflammatory cell recruitment not pre-
viously examined for this cytokine is extravasation from the
blood. Because we have defined a CD44-dependent adhe-
sion pathway pertinent to activated T cells, it was of inter-
est to investigate whether IL-15 has a role in the extravasa-
tion of T cells as well.
In the study presented here, we demonstrate that ECs di-
rectly respond to IL-15 in vitro with increased cell surface ex-
pression of HA and that, as with other proinflammatory stim-
uli (16), this responsiveness appears largely restricted to small
venular endothelial sources. Moreover, in an in vivo model
of peritoneal inflammation, IL-15 is sufficient to promote the
extravasation of superantigen-activated T cells, and this is de-
pendent on CD44 interactions with HA. Neither the in vitro
nor the in vivo activity is induced by IL-2, suggesting this is a
unique function for IL-15, although the shared receptor
chain 
 
b
 
 appears to be required. These results place a function
for IL-15 at the interface between the blood and vasculature,
a vital position in the sequence of T cell effector processes,
through regulation of CD44/HA interactions.
 
Materials and Methods
 
Chemicals and Reagents.
 
Biotinylated bovine proteoglycan (bPG)
extracted from bovine nasal cartilage (17) was provided by C.
Underhill (Georgetown University School of Medicine, Wash-
ington, DC). Rooster comb HA and Staphylococcal enterotoxin
B (SEB) were purchased from Sigma Chemical Co. 5-(and-6)-
carboxyfluorescein diacetate, succinimidyl ester (CFDA-SE), was
purchased from Molecular Probes, Inc. KM81, a rat anti–mouse
CD44 that blocks HA binding (18) and anti–mouse intracellular
adhesion molecule (ICAM)-1 (clone YN1/1.7.4; reference 19)
were obtained from the American Type Culture Collection and
anti–mouse vascular cell adhesion molecule (VCAM)-1 (clone
M/K-2.7; reference 20) was provided by Dr. P. Thorpe (Univer-
sity of Texas Southwestern Medical Center, Dallas, TX). Anti-
body was purified from tissue culture supernatants by Protein
A–Sepharose column chromatography. Rat anti–mouse H-2 (clone
M1/42) was provided by K. Fischer-Lindahl (Howard Hughes
Medical Institute, University of Texas Southwestern Medical
Center, Dallas, TX). Anti–human IL-15 was obtained from R&D
Systems, Inc. Rat anti–mouse TNF-
 
a
 
 and biotinylated anti–mouse
CD62P and anti-CD62E were obtained from PharMingen.
Murine TNF-
 
a
 
 (5 
 
3
 
 10
 
7
 
 U/mg), murine IL-1
 
b
 
 (2.2 
 
3
 
 10
 
7
 
U/mg), and human IFN-
 
g
 
 (10
 
7
 
 U/mg) were obtained from
Genzyme, Inc. Human IL-15 was obtained from R&D Systems
(ED
 
50
 
 in proliferation assays 0.5–2 ng/ml) and recombinant hu-
man IL-2 (10
 
7 
 
U/ml) was obtained from the Biological Response
Modifiers Program (Frederick, MD).
 
EC Culture and Stimulation.
 
SVEC4-10 is an SV40 transformed
murine LN EC line provided by K.A. O’Connell (Johns Hopkins
University School of Medicine, Baltimore, MD) (21). The TME-
3H3 endothelial line was similarly derived (22) and was provided
by A. Hamann (Medizinischen Klinick, Hamburg, Germany) and
J. Lesley (Salk Institute, San Diego, CA). LEII is a murine lung
capillary EC line derived by A. Curtis (University of Glasgow,
Glasgow, UK) and provided by P. Thorpe (University of Texas
Southwestern Medical Center, Dallas, TX). Cells were main-
tained in RPMI 1640–high glucose, 15% FCS plus 1 mM pyru-
vate, 2 mM glutamine, and 50 
 
m
 
m 
 
b
 
-mercaptoethanol. EC lines
were taken from frozen storage and used up to a maximum of
five passages. Human umbilical vein ECs (HUVECs) were ob-
tained from S.W. Caughman (Skin Center at Emory University,
Atlanta, GA) and were used upon reaching confluence or after
their first or second passages. Primary LN EC (1
 
8
 
LNEC) cultures
were made by pooling cervical and axial nodes from three ani-
mals, as described (23, 24). Organs were minced, rinsed to re-
move lymphocytes, treated with collagenase for 30 min at 37
 
8
 
C,
and plated on 35-mm culture dishes in supplemented IMDM
(20% FCS). These cultures at confluence showed the morpho-
logic and phenotypic characteristics indicating 
 
.
 
95% EC con-
tent, as previously described (1).
 
 
 
After reaching initial confluence,
cells were passaged and used directly or after one additional pas-
sage to fresh plates.
For stimulation of ECs, cells were passaged 24–48 h before ad-
dition of stimuli, when cultures were subconfluent. Stimuli were
added to 1 ml of culture medium as follows, except as noted in
dose–response experiments: TNF-
 
a
 
 and IFN-
 
g
 
 to a final con-
centration of 10 ng/ml; IL-2 and IL-15 to
 
 
 
a final concentration
of 50 ng/ml. Cells were maintained at 37
 
8
 
C in a 5% CO
 
2
 
 atmo-
sphere for 4 h, unless otherwise noted. Control cultures without
exogenous stimuli were incubated in parallel in all experiments.
Cells were harvested for FACS
 
®
 
 analysis and RNA isolation by
gentle pipetting after incubation with Versene (GIBCO BRL) for
5 min at 37
 
8
 
C. Anti–IL-15 or anti–TNF-
 
a
 
 was included in some 
11
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EC cultures at a final concentration of
 
 
 
100 ng/ml. For rolling assays,
ECs were grown in 35-mm Corning tissue culture dishes.
 
FACS
 
®
 
 Analysis.
 
5 
 
3
 
 10
 
5
 
 cells were stained with bPG-biotin
or primary antibody in 100 
 
m
 
l PBS/2% FCS for 30 min and then
washed with 500 
 
m
 
l of PBS/2% FCS. PE-labeled Streptavidin (SA-
PE; Caltag Labs.) or goat anti–rat immunoglobulin-FITC (Caltag
Labs.) was added for an additional 30 min. Cells were washed and
analyzed using a FACScan™ instrument and CellQuest™ software
(Becton Dickinson).
 
Reverse Transcription PCR.
 
Total RNA was isolated according to
the manufacturer’s instructions using RNAzolB (Biotecx). Reverse
transcription (RT)-PCR amplification was performed as previously
described (25). The following primer pairs were used: IL-2R
 
a
 
, 5
 
9
 
CCTACAAGAACGGCACCATCCTA/5
 
9 
 
CACCCCGTTTTC-
CCACACTTC; IL-2R
 
b
 
, 5
 
9 
 
CTCCGTGGACCTCCTTGACA-
TAAATGTGG/5
 
9 
 
TGTTTCGTTGAGCTTTGACCCTCACC-
TGG; IL-2R
 
g
 
, 5
 
9 
 
ATGTCCAGTGCGAATGAAGA/5
 
9 
 
CTC-
CGAACCCGAAATGTGTA; IL-15R
 
a
 
, 5
 
9 
 
CTCCAGGCTGA-
CACC/5
 
9 
 
CCATGGTTTCCACCTCAACACGGC. Cycling
conditions were 95
 
8
 
C for 60 s, 55
 
8
 
C for 90 s, and 72
 
8
 
C for 120 s.
PCR reactions were performed semi-quantitatively and com-
pared with 
 
b
 
-actin PCR amplifications run in parallel. For liquid
hybridization of RT-PCR products, oligonucleotide probe was
end-labeled with [
 
32
 
P]dCTP and T4 polynucleotide kinase. 5% (5
 
m
 
l) of PCR product from the IL-2R
 
a
 
 or 
 
g
 
 reactions were hy-
bridized in liquid phase (240 mM NaCl, 2.4 mM Tris/1 mM
EDTA) with 10 
 
m
 
l of 
 
32
 
P–end-labeled internal probe (IL-2R
 
g
 
chain: 5
 
9
 
 AGCTGAGATGGAAAAGCAGACA; IL-2R
 
a
 
 chain:
5
 
9
 
 GCTCCCTGCAGTGACCTGTAA-GGTTCTCTT) and ana-
lyzed by electrophoresis on a 4% acrylamide gel. Gels were vac-
uum dried and exposed to Kodak XAR-5 film. CTLL cells (Amer-
ican Type Culture Collection) maintained in the presence of IL-2
were used as a source of control RNA for the IL-2R
 
a
 
 and 
 
g
 
 chains
in liquid hybridization experiments.
 
Adhesion Assay under Flow Conditions.
 
Physiological flow con-
ditions were produced using a parallel plate flow chamber as pre-
viously described (1, 26). In brief, flow occurs over a 35-mm
tissue culture dish containing an adherent cell monolayer of ECs.
The culture dish and an opposing Plexiglas chamber are held 1.27 
 
3
 
10
 
2
 
2
 
 cm apart by a silicon gasket cut to form two flow chambers,
each 0.6 cm wide. Experiments were carried out at a wall shear
stress of 2.0 dynes/cm
 
2
 
 unless otherwise indicated. Murine LN
cells which had been cultured in vitro in the presence of SEB (50
 
m
 
g/ml) for 48 h, resulting in 12–30% of cells bearing activated
CD44 (2), were used. After equilibration of flow with medium
alone, SEB-activated LN cells were resuspended at a concentra-
tion of 3 
 
3
 
 10
 
6
 
 cells/ml in RPMI 1640 equilibrated to 37
 
8
 
C and
pulled continuously across the flow chamber. For blocking stud-
ies, antibody was added at saturating concentrations to the cell
suspension before flow. Interaction of lymphoid cells with the EC
monolayer after equilibration of flow was monitored for 10–15
min with an inverted phase contrast microscope connected to a
video camera and recorder. Only primary (rolling) adhesions were
analyzed, and rolling cells were scored visually. Data is reported
as the average number of rolling cells/mm
 
2
 
 per min, based on an
actual field of view of 0.6 mm 
 
3
 
 0.8 mm.
 
Short-term Homing Assay.
 
Short-term homing of fluorescently
labeled cells was performed as previously described (3), with the
following modifications. Donor BALB/c mice were injected in-
traperitoneally with 500 
 
m
 
l of sterile PBS or with 50 
 
m
 
g of the
superantigen SEB in 500 
 
m
 
l of PBS to provide a source of in
vivo–activated T cells. 20 h later, mesenteric LNs (MLNs) were
removed. MLN cells were fluorochrome labeled by resuspending
 
at a concentration of 10
 
7
 
 cells/ml in HBSS plus 2 
 
m
 
m CFDA-SE,
incubating them at room temperature for 20 min, and then wash-
ing the cells twice in HBSS. Recipient mice that had been injected
intraperitoneally 20 hours previously with SEB (50 
 
m
 
g), IL-15
(350 ng), IL-2 (200 ng), TNF-
 
a
 
 (200 ng), IFN-
 
g
 
 (200 ng), or IL-1
 
b
 
(200 ng) were then injected intravenously with 10
 
7
 
 fluorescent
donor cells/mouse in 500 
 
m
 
l HBSS. Some cytokine-injected re-
cipients were also given 200 
 
m
 
g blocking KM81 anti-CD44 or
control antibody at the time of donor cell injection. 2 h after the
infusion of labeled cells, recipient mice were killed and cells in
the peritoneal cavity were collected by lavage with 5 ml of 37
 
8
 
C
RPMI and analyzed for the presence of CFDA-labeled donor
cells. Some animals also received 200 ng/500 
 
m
 
l of anti–IL-15 or
anti–TNF-
 
a
 
 at the time of cytokine injection.
Depletion of V
 
b
 
8 T cells was performed using anti-V
 
b
 
8-biotin
(PharMingen) and Streptavidin-conjugated magnetic beads (Dy-
nal). Depletion of V
 
b
 
14 T cells was done using anti-V
 
b
 
14
(PharMingen) and goat anti–rat immunoglobulin-conjugated beads
(Dynal). 5 
 
3
 
 10
 
6
 
 cells were incubated for 20 min with 10
 
7
 
 beads in
1 ml RPMI 1640/5% FCS at 4
 
8C on a rocking platform. Vb81
or Vb141 T cells were removed by magnetic separation. After
depletion, ,1% of the remaining cells were shown to be Vb8 or
Vb14 cells by FACS® analysis. Samples were pooled and cell
numbers were readjusted to 107/500 ml before injection.
IL-2Rb–deficient mice were obtained by breeding heterozy-
gous animals purchased from The Jackson Laboratory (27). Ani-
mals were maintained at our facility under specific pathogen-free
conditions. Offspring were tested by PCR analysis of genomic
tail DNA and homozygous deficient and homozygous wild-type
animals were used at 4–5 wk of age.
Results
IL-15, But Not IL-2, Induces Increased HA Expression on
Cultured ECs. IL-15 has not been reported previously to
induce increased levels of adhesion molecule expression.
To examine the effect of IL-15 on the level of surface HA
expression, the LN-derived EC line SVEC4-10 was incu-
bated for 4 h in the presence of IL-15, TNF-a, IL-2, or
IFN-g. Using a biotinylated form of the HA-binding pro-
teoglycan bPG to detect cell surface HA, we found that
IL-15 treatment resulted in a marked increase in the amount
of surface HA expression, which was comparable to levels
seen with TNF-a treatment (reference 4 and Fig. 1 A). More-
over, HA surface expression appeared selectively induced,
as other endothelial adhesion molecules showed no substan-
tial alterations in levels of expression after IL-15 treatment
(Fig. 1 B), although VCAM-1 and P-selectin were both in-
creased on this cell line after LPS treatment (data not
shown). Kinetic studies further demonstrated that surface
HA expression was maximal at 4 h, consistent with the time
course previously demonstrated with other proinflamma-
tory cytokines (4). In contrast to IL-15, IL-2 had no effect
on the level of bPG binding on these ECs, although these
two cytokines have overlapping functions in many biologi-
cal systems (15). IFN-g (Fig. 1 A) and IL-12 (4) had no ef-
fect on HA expression, as previously reported. Also, bPG
staining of TNF-a–treated SVEC4-10 cells was blocked by
preincubating cells with soluble HA before staining with bPG
(1), indicating specificity of this reagent (17). Thus, the proin-12 IL-15 Regulates T Cell Trafficking through CD44
flammatory cytokine IL-15 acts as a potent and selective
regulator of surface HA expression.
To compare the effects of IL-15 and contrast them with
IL-2 on a variety of EC sources, we used several other EC
lines, including another SV40-transformed murine LN
line (TME-3H3), early passages of primary murine LN ECs
(18LNEC), a murine lung capillary EC line (LEII), and
HUVECs. Results are shown in Fig. 1 C, where it can be
seen that IL-15 increases HA expression on the other two
LN-derived ECs, also derived from microvascular venular
endothelium. In contrast, IL-15 had no effect on expression
of HA by the lung capillary line LEII or by HUVECs. This
is consistent with our prior results, which indicate that ECs
derived from microvenular sources, where leukocyte traf-
ficking predominantly occurs, selectively exhibit cytokine
inducible HA expression (4). In contrast to the effects of
IL-15, treatment with IL-2 had no effect on HA expression
in any of the ECs tested.
To determine the dose responsiveness of SVEC cells to
IL-15 and whether IL-2 has any influence at higher con-
centrations, dose–response curves were performed. Evalua-
tion of the response to IL-2 over a range of concentrations
indicated that this cytokine had no effect on HA expression
levels even at the highest concentrations used (Fig. 1 D).
The maximal response to human IL-15 was attained at 50
ng/ml. The dose–response curves suggest that IL-15 is ef-
fective in a concentration range comparable with those
seen in other cytokines (4). In contrast, murine IL-2 failed
to have any effect at concentrations as high as 400 ng/ml
(data not shown). Thus, unlike many of its other described
functions, IL-15 behaves in a manner completely distinct
from IL-2 with regard to endothelial HA induction.
ECs Produce the IL-2Rb and g Chains and IL-15Ra Chain,
But Not the IL-2Ra Chain. We next addressed the expres-
sion of IL-15R and IL-2R chains in these ECs. RNA was
prepared from SVEC4-10, TME-3H3, LEII, or 18LNEC to
examine these for the expression of IL-2Rb and g chain
message, the IL-2Ra chain, and IL-15Ra chain. As seen in
Fig. 2 A, agarose gel analysis of RT-PCR products revealed
significant expression in unstimulated ECs of both the
IL-2Rb and the IL-15Ra chains. Since ECs did not make
sufficient levels of either the IL-2Ra or g chains for direct
detection by ethidium staining, the PCR products for these
reactions were further analyzed by hybridization to specific
radiolabeled internal oligonucleotide probes. When the
IL-2Rg chain RT-PCR product was hybridized in liquid
phase to a 32P-labeled g chain probe, a band of the appro-
priate molecular weight (573 bp) was observed (Fig. 2 B).
However, similar analysis of the IL-2Ra chain RT-PCR
product gave no signal in any of the EC-derived RNAs
(Fig. 2 C), although the control IL-2–stimulated CTLL cells
did show an appropriate positive signal. Thus, ECs express
all three chains of the IL-15 cytokine receptor, but lack the
unique a chain specific to the IL-2R, consistent with the
relative pattern of induction of HA by these two cytokines.
It is notable that, similar to HUVECs, LEII expresses
mRNA for all IL-15R chains, yet these two EC lines are
not induced to express increased HA (Fig. 1 C). This sug-
Figure 1. Induction of bPG
staining on ECs in response to
cytokine treatment. (A) Levels of
cell surface HA increase follow-
ing treatment of SVEC4-10 cells
with TNF-a or IL-15. Cells
were incubated for 4 h with
TNF-a (10 ng/ml), IL-15 (50
ng/ml), IL-2 (50 ng/ml), or
IFN-g (10 ng/ml), harvested in
EDTA, stained with bPG-biotin
plus SA-PE, and analyzed by
FACS® for bPG binding. Un-
treated cells, which constitu-
tively express some HA, bind
background levels of bPG (solid line). After treatment with TNF-a or IL-
15, cells show even greater levels of staining (stippled line), whereas IL-2
has no effect. As previously shown, binding to bPG was not increased by
incubation with IFN-g (4). Baseline staining of SVEC4-10 cells with
SA-PE alone is indicated by the dashed line in the TNF-a panel. Prein-
cubating TNF-a–treated cells with soluble HA reduced bPG staining to
near background levels (heavy line). (B) Expression of ICAM-1, VCAM,
P-selectin, and E-selectin by SVEC4-10 cells before (stippled line) and af-
ter (solid line) IL-15 treatment. (C) TME-3H3, 18LNEC, LEII, and HU-
VEC cells were treated with human IL-15 (top) or IL-2 (bottom), as in A.
TME-3H3 and 18LNEC respond to IL-15 treatment by expressing in-
creased levels of HA, whereas LEII and HUVEC cells are not affected. In
contrast to IL-15, IL-2 had no effect on any of the EC lines or primary
ECs. Solid lines, untreated cells; stippled lines, treated cells. (D) Dose
dependence of increased HA levels in response to IL-15 treatment.
SVEC4-10 cells were incubated for 4 h with IL-15 or IL-2 at varying
concentrations, as shown. Results are reported as the mean fluorescence
intensity (MFI) of cells after staining with bPG-biotin plus SA-PE, as de-
termined by FACS® analysis. IL-2 had no effect on HA expression by
SVEC4-10 cells, even at 200 ng/ml, whereas IL-15 had a dose-dependent
effect on levels of surface HA, with changes seen at 10 ng/ml. Data
shown are the mean 6 SD from three separate experiments.13 Estess et al.
gests that differences either in receptor protein expression
or downstream signaling events in these cells account for
their IL-15 unresponsiveness. Thus, IL15Ra expression
appears not to be sufficient for responsiveness to IL-15.
Induction of Elevated Endothelial Surface HA Expression Re-
sults in Increased Rolling Interactions of SEB-activated T Cells under
Shear Stress Conditions. We have previously demonstrated
that the increases in HA induced by proinflammatory stimuli
are sufficient to markedly enhance rolling interactions of the
clonal T cell line, BW5147, under laminar flow analysis (4).
In addition, we have shown that TCR signaling through
conventional antigen or the superantigen SEB results in the
conversion of CD44 to its activated form. With SEB stim-
ulation, this activation of CD44 occurs selectively on the
SEB-stimulated (Vb8) subset of T cells (2). To determine
whether the levels of HA induced on ECs by IL-15 and
TNF-a had sufficient physiologic consequences to signifi-
cantly alter CD44-dependent rolling interactions, normal
peripheral LN T cells were stimulated in vitro with SEB and
subjected to laminar flow on unstimulated ECs and ECs
stimulated with IL-15 or TNF-a. Both SVEC4-10 and
TME-3 cells were used in a parallel plate adhesion assay after
24 h treatment with either cytokine, when complete con-
fluence and maximal HA expression of the monolayer was
assured. Fig. 3 shows that on both EC lines induction with
either IL-15 or TNF-a increased the number of rolling
cells four- to fivefold over that seen on unstimulated ECs,
although the cell density and viability of the monolayers
were equivalent. Furthermore, blocking anti-CD44 anti-
body specifically inhibited rolling by .80%, suggesting
VCAM-1/very late antigen (VLA)-4 or other interactions
do not substantially contribute to rolling under these con-
ditions. Unactivated T cells exhibited minimal rolling on
treated ECs. Thus, the changes in HA levels measured by
flow cytometry are sufficient for altering the EC capacity to
support CD44-dependent tethering and rolling interactions
under shear stress for normal activated T cells.
Intraperitoneal Administration of IL-15 Results in CD44-depen-
dent Recruitment of Activated T Cells into the Peritoneal Cavity.
Previous analysis has demonstrated that SEB, which specif-
ically activates the well-represented Vb8-bearing T cells,
induces peritoneal inflammation that results in CD44-medi-
ated recruitment of superantigen-activated T cells into the
inflamed site (3). To directly assess the ability of IL-15 to
generate an inflamed site similarly receptive to the CD44/
HA extravasation pathway, short-term homing assays were
performed using cytokines alone as the inflammatory stim-
ulus. Lymphocytes expressing activated CD44 were gener-
ated in vivo by intraperitoneally injecting donor mice with
SEB (3). 20 h later, MLN cells were isolated, washed, and
labeled with CFDA-SE. The fluorescent cells were then
injected intravenously into recipient mice that had received
an intraperitoneal injection of cytokine(s) or SEB (positive
control) 20 h previously. 2 h after intravenous injection of
Figure 2. Endothelial cells express RNA for the IL-15R but not for
IL-2R. (A) RT-PCR amplification of RNA from untreated 18LNEC,
SVEC4-10, TME-3H3, and LEII cells. Amplification was done with
primers specific for the murine IL-2Rb chain and the IL-15Ra chain as
shown. For comparison, results of amplification of b-actin RNA run in
parallel with the IL-15Ra chain are shown in the bottom panel. RT-
PCR amplification indicates that the primary ECs and the three EC lines
make detectable levels of RNA for each of the chains. (B) Autoradiogram
of the RT-PCR product resulting from amplification with primers spe-
cific for the mouse IL-2Rg or IL-2Ra chains. RT-PCR product was hy-
bridized in liquid phase with IL-2Rg– or a–specific 32P-labeled oligonu-
cleotide probes internal to the primer pairs used for amplification;
hybridized sample was separated from radiolabeled probe by acrylamide
gel electrophoresis and visualized by autoradiography. IL-2Rg–specific
product is clearly visible in all cells tested, whereas IL-2a–specific product
was seen only in the IL-2R1 control cell line CTLL.
Figure 3. Rolling of SEB-activated LN
T cells on TNF-a– or IL-15–treated
SVEC4-10 and TME-3H3 monolayers.
Cells were applied to feed solution already
equilibrated under flow at a wall shear stress
of 2.0 dynes/cm2 and perfused over EC
monolayers in the parallel plate flow assay.
Rolling was analyzed as described above
and the number of cells/mm2 per min roll-
ing across each monolayer was determined.
For blocking, KM81 anti-CD44 or anti–
H-2 was added to the T cell suspension be-
fore their introduction in the flow system.
Rolling of SEB-activated T cells on TNF-a
and IL-15–treated ECs compared with un-
treated ECs was significant for both SVEC
(P , 0.005) and TME3 (P , 0.001), and
anti-CD44 significantly reduced rolling
numbers compared with those on IL-15
treated ECs (P , 0.001).14 IL-15 Regulates T Cell Trafficking through CD44
donor cells, peritoneal exudate was collected from recipient
mice by peritoneal lavage and samples were analyzed cyto-
fluorometrically for CFDA (green) fluorescence to identify
cells that had trafficked to the site. As seen in Fig. 4 A, when
SEB-activated MLN cells were given to IL-15– or TNF-
a–treated recipients, significant extravasation of cells into
the peritoneum occurred. This was comparable to the levels
of emigration obtained in SEB-treated recipients. The migra-
tion of donor cells into IL-15– or TNF-a–treated sites was
dependent upon activated CD44, since coadministration of
an HA-blocking anti-CD44 antibody at the time of donor
cell transfer inhibited the transit of cells from blood into the
peritoneal cavity. Isotype control–matched anti–H-2 anti-
body did not inhibit cell migration. Moreover, magnetic
bead depletion of Vb8-bearing cells, the predominant lym-
phocyte population activated by SEB, completely ablated
emigration to the site, whereas depletion of the equally well-
represented non-SEB-responsive Vb14 population did not.
This indicated that, as with SEB (3), it is the activated T
cells that emigrate. In contrast, when SEB-activated donor
cells were transferred to mice that had received intraperito-
neal IL-2, IFN-g, or IL-1b, no significant emigration was
detected. Injection of unactivated donor cells from PBS-
treated animals also did not result in extravasation into the
peritoneal cavities of IL-15–treated recipient mice. Giving
optimal amounts of IL-15 and TNF-a together did not in-
crease migration, indicating that maximal recruitment is
achieved with either cytokine alone. This further suggests
that optimal HA expression is attained with either of these
treatments independently. Thus, TNF-a and IL-15, but
not IL-2 or IFN-g appear to alter the local vascular bed such
that it is receptive to CD44-mediated extravasation. These
results correlate well with our findings of HA regulation in
vitro using the same cytokines, and suggest that the in vivo
observations result from local changes in endothelial HA
induced by the administered cytokine. Representative two-
color immunofluorescence plots of cells recovered from the
peritoneal cavity of an IL-15–treated mouse are shown in
Fig. 4 B. 100,000 events were collected for each sample,
and those cells with green (CFDA) fluorescence in the sec-
Figure 4. Intraperitoneal cytokine treatment allows CD44-dependent short-term homing of SEB-activated T cells into inflamed mouse peritoneal
cavities. (A) CFDA-labeled MLN cells from SEB- or PBS-treated mice were injected intravenously into recipient mice that had received an intraperito-
neal injection of SEB or cytokine(s) 20 h earlier. Cells from donor mice were injected without antibody, with HA-blocking anti-CD44 mAb (KM81), or
with isotype-matched control anti–H-2 mAb. 2 h after injection, peritoneal cavities of recipient mice were lavaged and recovered cells were analyzed by
FACS® for CFDA fluorescence. Data are shown as the number of fluorescent cells/100,000 total cells analyzed and represent the mean 6 SEM from
three separate experiments (three mice/group per experiment). (B) Representative analysis of cells recovered from the peritoneal cavity of an IL-15 re-
cipient mouse. CFDA1 cells exhibit green fluorescence and are visible in the lower right hand quadrant. As shown in the right hand panel, anti-CD44
treatment of the recipient animal blocks the emigration of CFDA1 cells into the peritoneal cavity. 100,000 total events were collected. (C) Time course
of induction of inflamed peritoneal cavities after cytokine treatment for short-term homing of SEB-activated T cells. CFDA-labeled mesenteric LN cells
from SEB-treated mice were injected intravenously into either TNF-a–, IL-15–, or IL-2–treated recipients at varying time points after cytokine admin-
istration. Cells were recovered and analyzed as in A. No peritoneal accumulation of fluorescent cells is seen when injected at early time points after TNF-a
or IL-15 administration (#6 h); however, significant numbers of fluorescent cells are seen when transferred $16 h after cytokine treatment. No perito-
neal accumulation of fluorescent cells is seen at any time point in IL-2 injected mice. Data are shown as the number of fluorescent cells/100,000 cells an-
alyzed and represent the mean values 6 SEM from at least three experiments (three mice/group per experiment).15 Estess et al.
ond to third decade are scored as positive (donor derived).
KM81 anti-CD44 blocks the traffic of CFDA-labeled cells
into the recipient peritoneal cavity (Fig. 4 B, right).
Although IL-15 and TNF-a both induce HA and result
in trafficking of cells bearing activated CD44 into the treated
site, it was possible that the kinetics of their in vivo effects
differed. In addition, results with IL-2 could potentially have
been different at time points other than 20 h after treatment
if, for example, the timing of HA induction was altered. To
address these issues, we conducted short-term homing ex-
periments injecting donor cells at varying time points after
cytokine administration to recipient animals. With both
IL-15 and TNF-a, no significant migration of cells into the
peritoneal cavity was seen until 16 h after cytokine injec-
tion (Fig. 4 C), and both cytokines resulted in similar kinetics.
Moreover, no significant recruitment into the peritoneal
cavities of IL-2–injected animals was seen at any time point.
IL-15 Induced Short-term Homing Is Dependent on the Tradi-
tional Heterotrimeric IL-15R. An alternate IL-15R unrelated
to IL-2R chains is used by mast cells for their IL-15 respon-
siveness (28). To determine whether the conventional IL-15R
is required for CD44-dependent activated T cell extravasa-
tion in vivo, IL-2Rb–deficient mice (b2/2) were examined
for their ability to support IL-15–induced trafficking to the
peritoneum in the short-term homing model. When SEB-
activated normal MLN donor cells were transferred intra-
venously into b2/2 recipients treated intraperitoneally 20 h
previously with IL-15, there was no subsequent accumula-
tion of CFDA-labeled cells in the recipient peritoneal cavi-
ties (Fig. 5). However, when cells were transferred into b2/2
recipients treated intraperitoneally with SEB or TNF-a, hom-
ing into the peritoneal cavity occurred at levels similar to
those seen in wild-type recipients. Thus, the requirement for
IL-2Rb expression in the recipient tissues indicates that the
IL-15 effect is dependent on expression of an intact tradi-
tional IL-15R. In addition, the inflammatory recruitment
induced by SEB or TNF-a administration can occur in the
absence of IL-15R interactions. These data suggest that the
endothelial change(s) induced by TNF-a are intact in these
animals and are independent of IL-15 pathways.
IL-15 and TNF-a Induce HA Expression Independently.
It has been reported that TNF-a production in rheumatoid
arthritis is mediated at least in part by IL-15 (29). In addi-
tion, some ECs are known to produce IL-15 at basal levels
(30). We therefore investigated the possibility that TNF-a
or IL-15 induction of endothelial HA occurred indirectly
through the alternate cytokine and the resulting autocrine
feedback mechanism occurred through the respective re-
ceptor. Cells were cultured as described above with IL-15
or TNF-a, either with or without the inclusion of anticy-
tokine antibody. As illustrated in Fig. 6 A, the inclusion of
anti–IL-15 antibody in TNF-a–stimulated EC cultures had
no effect on the induction of HA. Likewise, the inclusion of
anti–TNF-a antibody in IL-15–stimulated EC cultures had
no effect on its induction of HA. Each antibody effectively
blocked HA stimulation in control cultures (i.e., IL-15/
anti–IL-15; TNF-a/anti–TNF-a). Together, the data sug-
gest that IL-15 does not cause increased HA expression by
increasing levels of TNF-a, nor does TNF-a result in in-
creased HA expression by affecting levels of IL-15. Thus, at
least two independent cell surface receptor pathways can
result in changes in HA expression.
Although IL-15 and TNF-a effects were clearly inde-
pendent when using isolated ECs in vitro, it was of further
interest to examine this issue in vivo using the short-term
homing assay, where cytokines may derive from additional
hematolymphoid or stromal cells within the peritoneum.
Therefore, IL-15 or TNF-a was introduced intraperito-
neally as above but in the presence or absence of blocking
anticytokine antibody. As seen in Fig. 6 B, anti–TNF-a
antibody did not inhibit the IL-15–induced recruitment to
the peritoneum. Anti–IL-15 did effectively prevent IL-15–
induced lymphocyte traffic, and anti–TNF-a likewise inhib-
ited TNF-a–induced migration, demonstrating functional
blocking by these antibodies. Thus, in this in vivo model,
IL-15 appears to alter CD44-mediated homing patterns in-
dependent of TNF-a, consistent with our in vitro results.
Discussion
A variety of glycoprotein adhesion receptors primarily
belonging to the immunoglobulin or selectin gene families
are regulated on endothelium by cytokines or other inflam-
matory stimuli: E-selectin expression is induced on a variety
Figure 5. SEB-activated T cells do not enter the peritoneal cavities of
IL-15–injected IL-2Rb chain–deficient mice. IL-2Rb knockout mice
were injected intraperitoneally with PBS, SEB, IL-15, or TNF-a, as indi-
cated. 20 h later, lymphocytes from MLN of SEB- or control-treated
BALB/c donor mice were isolated, CFDA labeled, and injected intrave-
nously into treated recipients. Cells were recovered and analyzed as in
Fig. 4. Peritoneal accumulation of fluorescent cells is seen in recipient
knockout mice injected intraperitoneally with either SEB or TNF-a;
however, no fluorescent donor cells are found in recipient mice when
treated intraperitoneally with IL-15. KM81 mAb blocks entry of activated
donor cells into peritoneal cavities of TNF-a–treated recipients, indicat-
ing CD44 dependence. Data are shown as the number of fluorescent
cells/100,000 cells analyzed and represent the mean 6 SEM from at least
three experiments (three mice/group per experiment).16 IL-15 Regulates T Cell Trafficking through CD44
of ECs stimulated with inflammatory agents such as TNF-a,
IL-1, or bacterial LPS; VCAM-1 can be induced by IL-1,
TNF-a, and IL-4; and levels of ICAM-1 have also been
shown to be influenced by cytokines on a variety of ECs
(31–33). We have recently added another class of molecule,
the glycosaminoglycan hyaluronan, to the list of endothelial
adhesion receptors that can be regulated in vitro, and have
demonstrated that such elevated HA expression results in
enhanced CD44-dependent primary adhesion interactions
with lymphocytes (4). Thus, proinflammatory stimuli exert
some of their effects by regulating the adhesion and thus
recruitment of leukocytes to inflamed sites. IL-15, to our
knowledge, has not been demonstrated previously to alter
endothelial adhesion molecule expression. These studies
show that, although adhesion glycoproteins generally do not
appear to be induced by IL-15, the expression level of HA
is increased to levels equivalent to that induced by other
proinflammatory stimuli (Fig. 1). Given the evidence sug-
gesting a role for the CD44/HA interaction in activated T
cell recruitment during immune and autoimmune responses
(1–3, 5), the selective upregulation of HA suggested a discrete
function for IL-15 in the recruitment of activated T cells.
The role of cytokines in influencing T cell recruitment
directly in vivo via the CD44/HA adhesion pathway had
not been examined previously. Intraperitoneal SEB super-
antigen challenge has been used to create an inflamed site
and to demonstrate the CD44 and HA dependence of T cell
extravasation into such an inflamed site in vivo (3). The studies
presented here demonstrate in a similar model that IL-15 as
well as TNF-a treatment have the same effect on CD44-
dependent T cell recruitment in the absence of further ex-
ogenous inflammatory stimuli. Other cytokines such as IFN-g
and IL-12, which did not result in the upregulation of EC
surface HA expression in vitro (Fig. 1 A, reference 4), also
had no effect in vivo (Fig. 4 A and data not shown). The
concordance of these results suggests that IL-15 and TNF-a
may be acting directly in vivo on the vascular endothelium
of the peritoneum. However, it should also be noted that
IL-1b, which could upregulate HA on ECs in vitro (4), had
no appreciable effect in this in vivo model. Like these other
cytokine receptors, IL-1bRs are expressed broadly, indicat-
ing that regulation does not occur purely at the level of re-
ceptor expression. Although IL-1 is known to be a potent
inducer of endothelial adhesion molecule expression (34),
its failure to induce lymphocyte recruitment in this model
may be due to a lack of responsiveness of the type of endo-
thelium in the peritoneum, the production in vivo of “de-
coy” IL-1R (type II) (35), or simply differences between in
vivo and in vitro models. The anatomic details of extrava-
sation into the peritoneum is complex and incompletely
understood, but can potentially occur directly through the
parietal peritoneum and/or through the serosal surfaces of
any of the visceral organs contained within the peritoneum.
Regardless, the high degree of specificity of the responsive-
ness supports the likelihood that IL-15 and TNF-a have
distinct roles, at least in part, in the recruitment of activated
T cells through a CD44-mediated pathway.
The functional activities ascribed to IL-15 have been de-
scribed as broadly analogous to those of IL-2 (for review
see reference 15). However, IL-15, but not IL-2, has been
shown to have a protective role against apoptosis in non-
lymphoid and lymphoid cells (10), and IL-15 has an effect
on mast cells through an apparently entirely unique recep-
tor unrelated to IL-2R components (28). In addition, it has
recently been described that IL-15 induces the production
by macrophages of another key proinflammatory cytokine,
TNF-a, although IL-2 was also demonstrated to have a
lesser effect (29). The role we have described for IL-15 on
ECs adds a further distinct bioactivity that appears to be
completely independent of IL-2 and also independent of
TNF-a. Analysis of mRNA expression shows no detect-
able levels of IL-2Ra message in any of the murine ECs
Figure 6. IL-15 and TNF-a
induce increased HA expression
via independent receptor path-
ways. (A) SVEC4-10 cells were
stimulated for 4 h with IL-15 or
TNF-a with or without the addi-
tion of either anti–IL-15 or anti–
TNF-a antibody, as indicated.
Inclusion of anti–TNF-a in
IL-15–stimulated cultures had no
effect on the increase of HA ex-
pression (upper right), nor did the
inclusion of anti–IL-15 in TNF-
a–stimulated cultures (lower left).
Each antibody effectively blocked
stimulation by the cytokine for
which it was specific, as shown
(upper left, lower right). Unstimu-
lated cells, bold line; stimulated
cells, solid line; stimulated cells
plus antibody, stippled line. (B) In
vivo administration of anti–
TNF-a does not alter the short-
term homing of activated T cells
in response to IL-15.17 Estess et al.
tested (Fig. 2). This is in agreement with previous reports
for human endothelium (12, 16), and is consistent with the
lack of an effect of IL-2 on endothelial HA expression (Fig. 1).
In addition, IL-2 had no effect on T cell recruitment in
vivo (Fig. 4), and therefore also does not appear to operate
through secondary cell types and/or cytokines that would
support T cell recruitment in this model. These observations
bring a functional relevance to the expression of IL-15Ra
on ECs, and do so in such a way as to further accentuate its
position in pathways of T cell function.
It is of interest that although all endothelial sources ex-
amined express IL-15Ra message as well as the coreceptor
chains IL-2Rb and IL-2Rg (Fig. 2), only a subset of these
responded to IL-15 with increased HA expression (Fig. 1).
Although it is possible that the level of message expression
does not reflect the protein products for these chains, the
evidence is also consistent with the possibility that IL-15R
expression alone is not sufficient for this response, and that
downstream signaling mechanisms determine the respon-
siveness of particular ECs to HA production. These obser-
vations will require further investigation.
The studies presented here add the induction of EC ad-
hesion receptors governing the initial phase of T cell adhe-
sion to the list of effector functions coordinated by IL-15, and
thus extend this cytokine’s influence to the endothelial lu-
menal surface. Recently, IL-15 has been shown to enhance
the transmigration of T cells through endothelium, although
the mechanism was not clarified (30). Thus, it is attractive to
suggest that under inflammatory conditions perivascular tis-
sues and endothelium produce an IL-15 chemotactic gradient
that induces endothelial HA production, thereby promoting
adhesion and subsequent coordinated migration through the
endothelium. Since IL-15 clearly has been shown to be a po-
tent chemoattractant for T cells (6, 36, 37), this may further
result in the migration of T cells towards the origin of the
stimulus within the tissues proper. IL-15 has been shown to
protect activated T cells from apoptosis (9, 38), and in partic-
ular has antiapoptotic effects on Fas-mediated death of acti-
vated T and B cells, as well as additional cell types in vivo
(10). This suggests that IL-15 may prolong the survival of ac-
tivated T cells under inflammatory states, favoring the exe-
cution of their effector functions. Recent observations that
IL-15 selectively stimulates a CD44hi CD8 T cell population
in vivo and in vitro further supports a role for this cytokine
in memory/effector T cell function (39) and is consistent
with the evidence presented here. Therefore, IL-15 has the
capacity to support multiple events in the life cycle of an
effector T cell, beginning with its initial attachment to en-
dothelium during extravasation, as demonstrated here, fol-
lowed by migration through the vascular barrier and within
tissues, and finally enhancement of survival within appro-
priate sites of antigenic challenge.
Although IL-15 and its various activities have been impli-
cated in the pathogenesis of rheumatoid arthritis (13, 29) and
may also play a prominent role in other chronic autoimmune
diseases (40, 41), another cytokine thought to be key in the
pathogenesis of rheumatoid arthritis is TNF-a. Approaches
directed at inhibiting the effects of TNF-a have in fact shown
significant therapeutic promise (42, 43). A significant relation-
ship between IL-15 and TNF-a has been demonstrated, in
that IL-15 was observed to induce TNF-a production from T
cells as well as secondarily from macrophages in a contact-
dependent fashion, suggesting that IL-15 acts upstream of
TNF-a during rheumatoid arthritis (29). Since both TNF-a
and IL-15 induce endothelial HA expression, and both can be
produced by ECs, it was of interest to examine whether these
cytokines acted coordinately or independently to achieve in-
creased HA levels. The presence of antibody to either cyto-
kine in culture had no effect on the ability of the other to in-
duce HA expression, suggesting that these cytokines act
independently at the receptor level and can each have their ef-
fects directly on ECs (Fig. 6 A). Moreover, administration of
anti–TNF-a antibody in vivo had no effect on the ability of
IL-15 to support T cell recruitment into the inflamed perito-
neum (Fig. 6 B). This further suggests that even in the pres-
ence of additional resident peritoneal cells, such as macro-
phages, which may be induced by IL-15 to secrete TNF-a, it
is not required for the CD44-mediated recruitment of T cells
in response to IL-15. Thus, although TNF-a may frequently
be a final mediator of inflammatory responses whose produc-
tion is influenced by IL-15, the evidence presented here sug-
gests that IL-15 has a more direct effect on endothelium itself
in T cell extravasation.
In summary, these studies establish a unique function for
IL-15 in affecting pathways of activated T cell recruitment
to an inflamed site by directly inducing endothelial HA ex-
pression, which allows activated T cells to bind via acti-
vated CD44. The results reinforce the key role that IL-15
plays throughout multiple stages of T cell effector function,
and helps to tie the expression of IL-15 and its receptor on
endothelium to the central theme of IL-15 in T cell–medi-
ated immune and autoimmune responses.
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